VITAMIN A ABSORPTION This was studied by the method of Paterson and Wiggins (1954) . Normal is a rise of more than 500 units/100 ml. URINE XYLOSE The results, determined by the method of Roe and Rice (1948) , were expressed as the percentage of the oral dose excreted in the five hours following administration. Normal is more than 25 %.
PLASMA IRON The normal range for men is 80-175 ,&g./100 ml. and for women 60-160 ,ug./100 ml., using Ramsay's (1958) method.
PLASMA VITAMIN B12 The method was based on that of Spray (1955) and Matthews (1962) using Lactobacillus leishmanii. The normal range is 150-900 ppg./ml.
PLASMA FOLIC ACID Plasma folic acid activity was determined with Lactobacillus casei. Normal range is 5-25 iLmg./ml.
PLASMA CORTISOL Plasma cortisol was determined by the method of Spencer-Peet, Daly, and Smith (1965) . Normal range is 5-26 ,ug./100 ml.
ADRENOCORTICAL RESPONSIVENESS This was assessed by estimating the plasma cortisol level before and 30 min.
after intramuscular injection of synthetic 8l.24 corticotrophin (Synacthen)1. A normal response is a rise of between 7-5 and 27 5 ,ug./100 ml. after 30 minutes (Wood, Frankland, James, and Landon, 1965 In November after 53 days of treatment with 2 mg. of Betnovate she was admitted for reassessment. The improvement had been maintained, and the patient said she had not felt so well for a year and could now eat 'loads of bread'. There was still some chemical evidence of malabsorption, but faecal fat was only 5-7 g. per day. A second reassessment took place after 120 days. The only abnormality detected was a low plasma folic acid level. Synacthen produced a normal adrenocortical response. There were no signs of hypercorticism. Treatment was continued with 2 mg. of Betnovate daily.
Details of the main clinical and laboratory findings are shown in Table II . A study of the effect of Betnovate on the plasma cortisol level (Otaki and Daly, to be published) showed that it caused less depression than its parent compound betamethasone. The absence of sideeffects noted here with Betnovate, and its relatively slight depressing effect on adrenal responsiveness, may be due to its being comparatively poorly absorbed, or to its having a less marked systemic effect for metabolic reasons. This is at present under investigation.
If Betnovate is poorly absorbed, its beneficial effects in idiopathic steatorrhoea and in ulcerative colitis and Crohn's disease (Gill et al., 1965) are presumably due to a surface effect. This does not appear to be the only method by which steroids act on the gut because Almy (1951) obtained good results with A.C.T.H. and Moeschlin and Meyer (1961) with intravenous prednisolone.
These preliminary observations appear to indicate that Betnovate is a promising new addition to the therapy of steatorrhoea, for it shows a dissociation between its therapeutic action on the intestine and its suppressive effect on the pituitary adrenal axis.
SUMMARY
A satisfactory clinical remission was induced in three cases of idiopathic steatorrhoea using not more than 3 mg. daily of oral Betnovate (betamethasone-17-valerate). Two patients were gluten-sensitive but all three patients were able to take a normal diet. Moderate chemical steatorrhoea persisted in one patient in whom vitamin A absorption failed to improve. In two patients the plasma vitamin B12 level fell during treatment. There was no evidence of steroid side effects after treatment for 95 to 204 days. Betnovate did not lead to adrenocortical suppression as judged by the Synacthen stimulation test but the response was reduced in one patient. Betnovate appears to be suitable for the long-term treatment ofidiopathic steatorrhoea but supplementary vitamin therapy may be necessary in some cases. 
